OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Help
Advanced
Search
14
Results
Show all
Save search
Copy query
Show results for
Unknown
(14)
Publication Date
Release Date
2021
(4)
2025
(3)
2022
(3)
2023
(2)
2020
(1)
2018
(1)
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
Sex Differences in Long COVID.
Not available
S-EPMC11755195
|
biostudies-literature
Cite
Olfactory Dysfunction After SARS-CoV-2 Infection in the RECOVER Adult Cohort.
Not available
S-EPMC12464792
|
biostudies-literature
Cite
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Not available
S-EPMC7556338
|
biostudies-literature
Cite
Dexamethasone in Hospitalized Patients with Covid-19.
Not available
S-EPMC7383595
|
biostudies-literature
Cite
Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.
Not available
S-EPMC6306365
|
biostudies-literature
Cite
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC7884931
|
biostudies-literature
Cite
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8830904
|
biostudies-literature
Cite
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8598213
|
biostudies-literature
Cite
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8084355
|
biostudies-literature
Cite
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC10957483
|
biostudies-literature
Cite
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets